Carla Etherton-Moore
Nurse Practitioner · Valley, ALNPI 1063478576
Payments from drug & device makers
Across 132 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$300
- Lilly USA, LLC$244
- Novo Nordisk$194
- GSK$187
- Amgen$154
- plus $826 from 23 others
What the payments were for
- Food & beverage$2,910100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $1,005 |
| AbbVie | 18 | $300 |
| Lilly USA, LLC | 11 | $244 |
| Novo Nordisk | 11 | $194 |
| GSK | 13 | $187 |
| Amgen | 3 | $154 |
| Pfizer | 6 | $100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $83 |
| Boehringer Ingelheim | 6 | $82 |
| Medtronic | 3 | $79 |
| Exact Sciences | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 3 | $39 |
| Viatris Specialty LLC | 2 | $39 |
| Abbott | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Lundbeck LLC | 1 | $29 |
| Radius Health, Inc. | 1 | $29 |
| Novartis | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Bayer | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Corium, LLC | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,910 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 180 | $203,493 |
| OzempicSemaglutide | 53 | $57,082 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 101 | $47,593 |
| FarxigaDapagliflozin Propanediol | 45 | $38,157 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $37,805 |
| EliquisApixaban | 41 | $30,571 |
| JardianceEmpagliflozin | 38 | $30,145 |
| LinzessLinaclotide | 27 | $24,202 |
| JanuviaSitagliptin Phosphate | 29 | $17,540 |
| EntrestoSacubitril/Valsartan | 16 | $13,335 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 98 | $13,136 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,637 |
| Spiriva HandihalerTiotropium Bromide | 19 | $10,346 |
| VerquvoVericiguat | 11 | $8,500 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $244 | $203,493180 claims |
| Novo NordiskOzempic | $194 | $57,08253 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,005 | $54,96680 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $187 | $45,14467 claims |
| PfizerEliquis, Premarin, Prempro | $100 | $37,49069 claims |
| Boehringer IngelheimJardiance | $82 | $30,14538 claims |
| AbbVieLinzess | $300 | $24,20227 claims |
| NovartisEntresto | $26 | $13,33516 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $1,89917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Valley
- Erin TannerAlabaster$141K
- Ardie Pack MabienMobile$126K
- Ginger McDanielBirmingham$27K
- Audrey MorganMontgomery$24K
- Hollie CrutchfieldDothan$22K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
- Ashley HodgensMontgomery$19K
- Lisa PeoplesBirmingham$17K
- Samantha WeaverBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.